化疗联合免疫治疗在提高肝癌合并门静脉癌栓术后疗效中的作用研究

The role of chemotherapy combined with immunotherapy in improving the postoperative efficacy of hepatocellular carcinoma combined with portal vein thrombus Overland

目的研究肝癌合并门静脉癌栓患者实施术后行化疗联合免疫治疗的临床效果。方法选取2016年10月至2019年10月该院收治的肝癌合并门静脉癌栓患者56例,采用奇偶数法分为研究组和参照组,每组28例。参照组治疗措施为肿瘤切除联合癌栓取出术,研究组于术后行化疗联合免疫治疗。对比两组患者治疗前后血清生物标志物及生存率情况。结果两组患者治疗前血清生物标志物水平比较,差异均无统计学意义(P>0.05);研究组患者治疗后血清甲胎蛋白、胰岛素样生长因子Ⅱ、胰岛素样生长因子结合蛋白2水平均明显低于参照组,1、2、3年生存率均明显高于参照组,差异均有统计学意义(P<0.05);两组患者并发症及不良反应发生率比较,差异无统计学意义(P>0.05)。结论肝癌合并门静脉癌栓患者实施术后行化疗联合免疫治疗的临床效果显著。

Objective To study the clinical effect of postoperative chemotherapy combined with immunotherapy in patients with liver cancer complicated by portal vein thrombosis.Methods 56 patients with liver cancer complicated with portal vein thromboembolus admitted to our institute were selected from October 2016 to October 2019 as the time range of this study.They were divided into the experimental group and the reference group by parity method,with 28 cases each.The treatment measures of the control group were tumor resection combined with tumor thrombotomy,while the experimental group received chemotherapy combined with immunotherapy after surgery.Serum biomarkers and survival rates of the two groups were compared before and after treatment.Results(1)in patients with hepatic carcinoma with portal venous tumor emboli before treatment serum biomarkers have consistency,P>0.05,the experimental group after treatment serum AFP,Ⅱinsulin-like growth factor,insulin-like growth factor binding protein 2 is lower than the control group,has obvious differences between groups,(P<0.05).(2)the 1-year survival rate(75.00%),2-year survival rate(57.14%),and 3-year survival rate(35.71%)in the experimental group were higher than those in the control group(35.71%,21.43%,10.71%),with significant differences between the groups(P<0.05).(3)the incidence of pleural effusion,gastrointestinal bleeding,nausea and vomiting,abnormal white blood cells,abnormal platelets and other adverse reactions and complications(28.57%,10.71%)were consistent in patients with liver cancer complicated by portal vein thrombosis(P>0.05).Conclusion Postoperative chemotherapy combined with immunotherapy is effective in patients with liver cancer complicated with portal vein thrombus.